ClinicalTrials.gg
Not yet recruitingNCT07794111Updated Aug 31, 2026

A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.

A Phase 1 interventional study of TQF6422 Injection and TQF6422 Placebo in Obesity / Overweight, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
266th of 502
108 · median 120
Started
2026
with 133 others
Phase 1
93 of 600
29 open now
Primary completion
2028-06
later than 226 of 280 live
Registered
554th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 266th largest by planned enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 93 in phase 1, reaches primary completion later than 226 of the 280 other live ones, and was the 554th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.

03

Conditions studied

  • Obesity / Overweight
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese male or female trial participants aged ≥18 years (inclusive) and ≤55 years (inclusive).
  2. Participant body weight ≥50 kg, with body-mass index () of 24-40 kg/m² (end-points included).
  3. At screening, the following findings shall be within normal limits, or deemed clinically insignificant by the Investigator despite being abnormal and not meeting exclusion criteria: vital signs, physical examination, 12-lead (ECG), chest X-ray, abdominal ultrasound, and clinical laboratory tests (including but not limited to hematology, urinalysis, serum biochemistry, coagulation function, serological virology, and thyroid function).
  4. Negative antibody (HIV-Ab) test.
  5. For female participants:

    1. Non-: including surgical sterilization performed at least 6 weeks prior to screening visit (documented tubal ligation, hysterectomy, or bilateral oophorectomy), or status for ≥12 months prior to screening visit (confirmed by follicle-stimulating hormone (FSH) level ≥40 IU/L); OR
    2. Child-bearing potential: must be non-pregnant and non-lactating, and must agree to use effective (at least one highly-effective) non-pharmacological measures from 14 days before screening, throughout the study period, and for 6 months after study drug administration. Serum pregnancy test shall be negative with human chorionic gonadotropin (hCG) \<5 mIU/mL at screening and baseline (D-1). Participants shall not donate ova during this period.
  6. Male participants with female partners of child-bearing potential must agree to use effective (at least one highly-effective) non-pharmacological contraceptive measures from 14 days before screening, throughout the study period, and for 6 months after study drug administration. Male participants shall not donate sperm during this period.
  7. Voluntarily provide written prior to trial participation, with full understanding of trial content, procedures and potential adverse reactions; able to communicate adequately with the Investigator, and understand and comply with all study-related requirements.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from enrollment:

  1. Presence of clinically-significant ongoing disease, or history of chronic/severe disease, including but not limited to circulatory, lymphatic, respiratory, endocrine, urinary, digestive, nervous, psychiatric, or infectious diseases, malignant neoplasms, severe trauma; or other conditions judged by the Investigator to be exclusionary or likely to confound interpretation of trial results.
  2. History of second-degree or higher cardiac conduction block, or PR interval >220 ms; risk factors or history of torsades de pointes ventricular tachycardia, including but not limited to unexplained syncope, long- syndrome, heart failure; OR any abnormal 12-lead at screening judged by the Investigator to increase risks associated with study participation.
  3. History of gastrointestinal surgery causing malabsorption (except for endoscopic resections such as gastric polypectomy), or long-term use of medications directly affecting gastrointestinal motility.
  4. Use within 3 months prior to screening, or ongoing use of medications known to significantly affect body weight (regardless of therapeutic indication), including: GLP-1R agonists, GLP-1R/GIPR agonists, GLP-1R/GCGR agonists, systemic (intravenous, oral or intra-articular), metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, thiazolidinediones (TZDs), tricyclic antidepressants, psychotropic or sedative agents (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, lithium salts).
  5. Known comorbid diseases affecting the skeletal-muscle system (e.g., myasthenia gravis, muscular dystrophy); or use of any medications or supplements known to affect muscle anabolism/catabolism within 3 months prior to screening.
  6. Sunburn, scar tissue, tattoos covering >25 % of total body surface area, open ulcers or branding at screening, judged by the Investigator to interfere with interpretation of cutaneous adverse reactions.
  7. Clinically-significant infection at screening, including but not limited to upper respiratory tract infection, lower respiratory tract infection, herpes simplex, herpes zoster, requiring antibiotic or antiviral therapy.
  8. Receipt of live-virus vaccine within 4 weeks prior to randomization, or planned live-virus vaccination during the study.
  9. Surgical procedure performed within 4 weeks prior to randomization, or planned surgery during the study.
  10. Blood transfusion, blood loss or blood donation exceeding 400 mL within 3 months prior to screening (excluding physiological menstrual blood loss in female subjects), and/or donation within 2 weeks prior to study drug administration.
  11. Use of any prescription, over-the-counter, or herbal medicines within 4 weeks prior to randomization (if 5-half-lives of the relevant drug exceed 14 days, the 5-half-life period shall apply).
  12. History of needle-phobia or venipuncture-related vasovagal syncope, difficult-to-access venipuncture, or intolerance to venous puncture.
  13. Known to any component of TQF6422 injection, or prior history of severe allergic reactions (including any food or drug allergy).
  14. History of substance abuse within 3 months prior to screening, or positive urine drug screen.
  15. Cigarette smoking >10 cigarettes per day, or equivalent nicotine-containing product use within 3 months prior to screening; or inability to abstain from all tobacco-containing products during the study.
  16. Chronic alcohol abuse, or alcohol intake exceeding 14 units per week within 3 months prior to screening (1 unit = 360 mL beer, or 45 mL 40 %-proof spirit, or 150 mL wine); or inability to refrain from alcohol during the study; or positive alcohol breath test.
  17. Habitual excessive intake of caffeine-containing beverages or food within 4 weeks prior to randomization (e.g., coffee, tea, milk-tea, chocolate, cola, energy drinks). Daily caffeine intake shall not exceed 6 units. 1 caffeine-unit = 1 cup coffee (177.4 mL) = 2 cans cola (354.9 mL) = 1 cup tea (354.9 mL) = ½ can energy drink = 85 g chocolate.
  18. Consumption of grapefruit, Seville-orange or their juices within 7 days prior to first-dose, or inability to discontinue consumption of grapefruit, Seville-orange or their juices during the study.
  19. Special-dietary requirements that prevent adherence to standard-diet instructions.
  20. Participation in any drug or medical-device clinical trial within 3 months prior to screening, or planned participation in another clinical trial during this study.
  21. Body-weight change >5 % within 3 months prior to screening.
  22. Positive surface antigen (HBsAg), antibody (HCV-Ab), or treponema pallidum antibody (TP-Ab).
  23. Meeting any of the following clinical laboratory criteria at screening:

    1. (ALT) and/or aspartate aminotransferase (AST) >1.0×, and/or total (TBIL) >1.2×ULN;
    2. Estimated (eGFR) calculated by CKD-EPI formula \<90 mL/min/1.73 m²;
    3. Serum creatine kinase (CK) >1.2×ULN;
    4. Serum amylase or lipase >1.0×ULN.
  24. Any other condition or factor judged by the Investigator rendering the subject unsuitable for study participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Part A: TQF6422 Injection (Single Dose)

    Participants in this arm will receive a single dose of TQF6422 Injection.

    Drug: TQF6422 Injection

  • Placebo comparator
    Part A: TQF6422 Placebo (Single Dose)

    Participants in this arm will receive a single dose of placebo matching TQF6422 Injection.

    Drug: TQF6422 Placebo

  • Experimental
    Part B: TQF6422 Injection (Once Weekly)

    Participants in this arm will receive TQF6422 Injection administered once weekly (QW) for multiple doses.

    Drug: TQF6422 Injection

  • Experimental
    Part B: TQF6422 Injection (Once Every 4 Weeks)

    Participants in this arm will receive TQF6422 Injection administered once every 4 weeks (Q4W) for multiple doses.

    Drug: TQF6422 Injection

  • Placebo comparator
    Part B: TQF6422 Placebo (Once Weekly or Once Every 4 Weeks)

    Participants in this arm will receive placebo matching TQF6422 Injection administered Once Weekly or Once Every 4 Weeks.

    Drug: TQF6422 Placebo

Interventions

  • DrugTQF6422 Injection

    TQF6422 injection is an anti-ActRIIA/IIB monoclonal antibody.

  • DrugTQF6422 Placebo

    A placebo matching TQF6422 Injection in appearance, dosage form, and route of administration, but containing no active ingredient.

06

What researchers measure

Primary outcomes

  1. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to day84 in part A and day112 in part B.

Secondary outcomes

  1. Time-to-maximum concentration( Tmax)

    Time-to-maximum concentration of TQF6422

    Time frame: Predose to Day 84 after administration in part A ;Predose to Day 112 after administration in part B.

  2. Peak concentration (Cmax)

    Maximum plasma drug concentration of TQF6422

    Time frame: Predose to Day 84 after administration in part A ;Predose to Day 112 after administration in part B.

  3. Area under the concentration-time curve(AUC)

    Area under the plasma concentration-time curve of TQF6422

    Time frame: Predose to Day 84 after administration in part A;Predose to Day 112 after administration in part B.

  4. Apparent volume of distribution (Vd/F)

    Apparent Volume of Distribution at the Terminal Phase divided by Bioavailability.

    Time frame: Predose to Day 84 after administration in part A;Predose to Day 112 after administration in part B.

  5. Apparent Clearance (CL/F)

    The apparent volume of plasma from which the drug is completely removed per unit time, adjusted for bioavailability

    Time frame: Predose to Day 84 after administration in part A;Predose to Day 112 after administration in part B.

  6. Plasma half life (t1/2)

    The time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half of TQF6422

    Time frame: Predose to Day 84 after administration in part A;Predose to Day 112 after administration in part B.

  7. Change from baseline and percentage change from baseline in total body weight

    Body weight will be measured with shoes and headwear removed.

    Time frame: at Week 4, Week 8, and Week 12 following the last administration.

  8. Change from baseline and percentage change from baseline in waist circumference

    Waist circumference should be measured in the horizontal plane, at the midpoint between the inferior margin of the last palpable rib and the top of the iliac crest.

    Time frame: at Week 4, Week 8, and Week 12 following the last administration.

  9. Change from baseline in total fat mass (TFM)

    Change from baseline in the TFM will be measured by dual-energy X-ray absorptiometry (DXA) after the last dose

    Time frame: at Week 4, Week 8, and Week 12 following the last administration.

  10. Change from baseline in total lean body mass (LBM)

    Change from baseline in the LBM will be measured by dual-energy X-ray absorptiometry (DXA) after the last dose

    Time frame: at Week 4, Week 8, and Week 12 following the last administration.

  11. Myostatin and Activin A levels

    Determine the changes in serum Myostatin and Activin A levels from baseline at each visit.

    Time frame: Up to day 84 after administration in part A;Up to day 112 after administration in part B.

  12. Fasting plasma glucose

    Changes and percentage changes in fasting plasma glucose after administration.

    Time frame: Up to day 84 after administration in part A;Up to day 112 after administration in part B.

  13. Fasting insulin

    Changes and percentage changes in fasting insulin after administration.

    Time frame: Up to day 84 after administration in part A;Up to day 112 after administration in part B.

  14. Glycated hemoglobin (HbA1c)

    Changes and percentage changes in HbA1c after administration.

    Time frame: Up to day 84 after administration in part A;Up to day 112 after administration in part B.

  15. Lipid parameters

    Changes and percentage changes in Lipid parameters after administration.

    Time frame: Up to day 84 after administration in part A;Up to day 112 after administration in part B.

  16. Anti-drug antibody (ADA) levels

    Test ADA status in biological sample via validated methodology.

    Time frame: Predose to Day 84 after administration in part A ;Predose to Day 112 after administration in part B.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2028, 21 months later.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 21 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartEst.
Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07794111
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Xuening Li, Master
Contact
li.xuening@zs-hospital.sh.cn
86-21-31587862

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion